OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Blum Details Upcoming Research in Renal Medullary Carcinoma

February 13th 2023

Kyle A. Blum, MD, MS, explains how renal medullary cancer, like most rare cancers, can be difficult to study. However, there are several ongoing studies that include this patient population.

Dr. Sahin on the Background of the IMbrave 151 Trial in Biliary Tract Cancer

February 11th 2023

Ilyas Sahin, MD, discusses the background and findings of the phase 2 IMbrave 151 trial in advanced biliary tract cancer.

Dr. Walden on the RNA Expression of Homologous Recombination Genes in CRC

February 10th 2023

Daniel Walden, MD, discusses the association of low expression of RNA of wild-type homologous recombination genes and survival in colorectal cancer.

Dr. Friedland on a Multimodal Screening Blood Test to Detect CRC

February 10th 2023

Shai Friedland, MD, discusses a multimodal screening blood test for advanced adenomas in colorectal cancer.

Dr. Mehta on Frontline and Adjuvant Treatments in ESCC

February 10th 2023

Rutika Mehta, MD, MPH, discusses which patients with esophageal squamous cell carcinoma may benefit most from the different frontline treatment options available and highlights key treatment developments with adjuvant immunotherapy plus chemotherapy.

Dr. Rogers on the Potential for ctDNA to Aid Second-line Treatment Decisions in mCRC

February 10th 2023

Sherise Rogers, MD, MPH, discusses the potential of utilizing circulating tumor DNA to help guide second-line treatment decisions in patients with metastatic colorectal cancer.

Dr. Montero on the FDA Approval of Elacestrant in ER+/HER2– Breast Cancer

February 10th 2023

Alberto Montero, MD, MBA, CPHQ, discusses the significance of the FDA approval of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

Dr. Wander on the Role of NF1 Mutations on CDK4/6 Resistance in Breast Cancer

February 10th 2023

Seth Wander, MD, PhD, discusses the investigation of resistance to CDK4/6 inhibitors and the role of NF1 mutations in breast cancer.

Dr. Neven on the Relationship of Cell Cycle Genes and Outcomes in HR+/HER2– Breast Cancer

February 10th 2023

Patrick Neven, MD, discusses the association between cell cycle–related genes and outcomes for patients with hormone receptor–positive/HER2-negative advanced breast cancer treated on the phase 3 MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials.

Dr. Linhares on Patient-Reported Outcomes From the OUTREACH Trial in R/R LBCL

February 10th 2023

Yuliya Linhares, MD, discusses the trial design, methodology, and key efficacy and safety results from the phase 2 OUTREACH trial (NCT03744676) evaluating lisocabtagene maraleucel (liso-cel; Breyanzi) in relapsed/refractory large B-Cell lymphoma (LBCL).

Dr. Andikyan on the Rationale of Using HIPEC in Ovarian Cancer

February 10th 2023

Vaagn Andikyan, MD, discusses the utilization of hyperthermic intraperitoneal chemotherapy in patients with stage III epithelial ovarian cancer.

Dr. Perez Perez on Results From a Retrospective Study of Polatuzumab Regimens in R/R LBCL

February 10th 2023

Ariel Perez Perez, MD, discusses key results and clinical implications from a retrospective study of polatuzumab-vedotin plus rituximab with or without bendamustine in relapsed/refractory large B-cell lymphomas.

Dr. Kumar on Immunotherapy Combinations in RCC

February 10th 2023

Rohit Kumar, MD, discusses the benefits of combining immunotherapy agents with each other or with TKIs in patients with renal cell carcinoma and the unmet needs that remain for patients with RCC who do not respond to immunotherapy.

Dr. Singh on Treatment Updates in Urothelial Carcinoma

February 10th 2023

Vikas Kumar Singh, MD, discusses findings from the phase 3 GETUG-AFU V05 VESPER (NCT01812369) and JAVELIN Bladder 100 (NCT02603432) trials in patients with bladder cancer.

Dr. Ravi on Ongoing Investigation of PSMA-targeted Therapies in mCRPC

February 9th 2023

Praful K. Ravi, MB, BChir, MRCP, discusses ongoing and future clinical trials investigating the use of prostate-specific membrane antigen-targeted therapies in metastatic castration-resistant prostate cancer.

Dr. Kundranda on the Sequencing of Second-Line Therapies in HCC

February 9th 2023

Madappa Kundranda, MD, PhD, discusses the sequencing of second-line therapies in hepatocellular carcinoma.

Dr. Bidard on the FDA Approval of Elacestrant in ER+/HER2– Metastatic Breast Cancer

February 8th 2023

François-Clément Bidard, MD PhD, discusses the significance of the FDA approval of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer and key efficacy and safety data from the phase 3 EMERALD trial.

Dr. Choudhury on the Potential Benefit of PARP Inhibitor Use in mCRPC

February 8th 2023

Atish D. Choudhury, MD, PhD, discusses key biomarkers that may assist in the prediction of PARP inhibitor benefit in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Rhee on the Benefit of Zanubrutinib Vs Ibrutinib in R/R CLL

February 8th 2023

June-Wha Rhee, MD, discusses the benefit of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia, as well as the incidence of cardiac disorders associated with the BTK inhibitors.

Dr. Fallon on Supportive Care Considerations in R/R Multiple Myeloma

February 8th 2023

Michael J. Fallon, MD, discusses supportive care considerations for patients with relapsed/refractory multiple myeloma.